TREML1
Trem-like transcript 1 protein
Also known as: dJ238O23.3, TLT1, TRML1_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q86YW5
- Gene
- TREML1
- Ensembl
- ENSG00000161911
- Chromosome
- 6
- Canonical length
- 311 aa
- Protein class
- Plasma proteins, Predicted membrane proteins
- Subcellular location
- Nuclear speckles,Golgi apparatus,Plasma membrane,Cytosol
OverviewNCBI Gene
This gene encodes a member of the triggering receptor expressed on myeloid cells-like (TREM) family. The encoded protein is a type 1 single Ig domain orphan receptor localized to the alpha-granule membranes of platelets. The encoded protein is involved in platelet aggregation, inflammation, and cellular activation and has been linked to Gray platelet syndrome. Alternative splicing results in multiple transcript variants [provided by RefSeq, Nov 2012]
Canonical amino-acid sequenceUniProt
311 residues, UniProt reviewed canonical sequence.
>Q86YW5|TREML1
1 MGLTLLLLLL LGLEGQGIVG SLPEVLQAPV GSSILVQCHY RLQDVKAQKV WCRFLPEGCQ
61 PLVSSAVDRR APAGRRTFLT DLGGGLLQVE MVTLQEEDAG EYGCMVDGAR GPQILHRVSL
121 NILPPEEEEE THKIGSLAEN AFSDPAGSAN PLEPSQDEKS IPLIWGAVLL VGLLVAAVVL
181 FAVMAKRKQG NRLGVCGRFL SSRVSGMNPS SVVHHVSDSG PAAELPLDVP HIRLDSPPSF
241 DNTTYTSLPL DSPSGKPSLP APSSLPPLPP KVLVCSKPVT YATVIFPGGN KGGGTSCGPA
301 QNPPNNQTPS SLocalizationUniProt · AlphaFold · HPA
Whether an antibody against TREML1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.57
- Highest tissue expression
- 7.7 nTPM
Expression across tissuesHPA
Tissue
- bone marrow: 7.7 nTPM
- spleen: 6.9 nTPM
- lymph node: 4.4 nTPM
- tonsil: 3.6 nTPM
- thymus: 3.1 nTPM
- spinal cord: 2.7 nTPM
Single-cell type
- platelets: 2,534 nCPM
- megakaryocytes: 519 nCPM
- microglia: 28 nCPM
- megakaryocyte progenitors: 27 nCPM
- erythrocytes: 4.1 nCPM
- cdc: 3.5 nCPM
Immune cell
- total PBMC: 105 nTPM
- basophil: 91 nTPM
- neutrophil: 10 nTPM
- eosinophil: 2.8 nTPM
- intermediate monocyte: 1.7 nTPM
- classical monocyte: 1.6 nTPM
Brain region
- thalamus: 5.6 nTPM
- white matter: 4.9 nTPM
- medulla oblongata: 4.8 nTPM
- pons: 3.9 nTPM
- spinal cord: 3.7 nTPM
- midbrain: 3.4 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.84
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.14
- DepMap mean gene effect
- -0.06
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of TREML1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads TREML1 as an antibody target. Whether an autoantibody or antibody against TREML1 could matter depends on whether native TREML1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
TREML1 is annotated at the cell surface, where native TREML1 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label TREML1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...